Follow us on  LinkedFit for Health LinkedIN

Frequently Asked Questions (FAQ) - Scope

Question details: 
Will EDCTP under its second programme support early clinical development work such as clinical grade product development, manufacture of clinical grade materials, or early phase I clinical trials of vaccines and products?
Answer: 

Pre-clinical development cannot be supported by EDCTP. EDCTP only supports phase I to IV clinical trials. The grant that EDCTP provides, in case a proposal is successful, can be used in part to cover the costs associated with manufacturing a product that is necessary to conduct the clinical trial (phase I and beyond), on the condition that accounting conditions for recognising expenditures are met.
Under no circumstances can any (manufacturing) cost incurred before the start of the EDCTP-funded project, be counted as cofunding to the project (in case cofunding is requested). Requests for funding of early pre-clinical work can, for example, be directed to other Horizon2020 programmes.

Question details: 
What are the differences between the currently open call ‘Strategic actions supporting large scale trials’, and the already closed call ‘Diagnostic tools for poverty-related diseases’, also a RIA action with two stages?
Answer: 

The ‘Strategic actions’ call supports clinical research activities which are part of a large-scale clinical trial that has the potential to achieve rapid advances in the clinical development of new or improved medical interventions against poverty-related and neglected infectious diseases. In short, the ‘Strategic actions’ call focuses on large-scale clinical trials. The ‘Diagnostics’ call is intended to fund projects that aim to validate the clinical performance and/or implementation of new or improved diagnostic tools and technologies for the detection of any of the PRDs (including as co-infections).

Answer: 

It can be considered if it is presented as comorbidity with a poverty-related infectious disease within the remit of the call.

Answer: 

EDCTP provides funding for research on infectious diseases, especially poverty-related and neglected and/or emergent infectious diseases prevalent in sub-Saharan Africa.